-
441
Single factor detection results.
Published 2024“…The conclusions are as follows: (1)Park vitality varied dramatically between different periods, with park vitality being higher on holidays than on weekdays. …”
-
442
Types of interaction between two factors.
Published 2024“…The conclusions are as follows: (1)Park vitality varied dramatically between different periods, with park vitality being higher on holidays than on weekdays. …”
-
443
Research frameworks.
Published 2024“…The conclusions are as follows: (1)Park vitality varied dramatically between different periods, with park vitality being higher on holidays than on weekdays. …”
-
444
Table 1_Case report: Clinical and immunohistochemical manifestations of suspected Sjogren's disease in a dog.xlsx
Published 2024“…Ocular discomfort improved dramatically decreasing the need for topical lubricants; however, tear production failed to improve likely due to extensive lacrimal gland atrophy. …”
-
445
Model index comparison.
Published 2024“…The conclusions are as follows: (1)Park vitality varied dramatically between different periods, with park vitality being higher on holidays than on weekdays. …”
-
446
Image 1_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
447
Image 5_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
448
Table 1_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
449
Image 2_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
450
Image 4_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
451
Image 9_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
452
Image 8_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
453
Image 7_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
454
Table 1_Schistosomiasis in Ghana from baseline to now: the impact of fifteen years of interventions.docx
Published 2025“…Prevalence of schistosomiasis decreased dramatically at first impact assessment, with overall prevalence at 3.5% (95% CI 2.6–4.7) and remained low in recent surveys at 6.8% (95% CI 6.1–7.6), which represents a 67.8% reduction from baseline to current prevalence.…”
-
455
Image 11_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
456
Table 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
457
Image 3_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
458
Image 6_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
459
Image 10_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
-
460
Image 3_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif
Published 2025“…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”